nach oben

26.02.2021 | Typ-2-Diabetes | Fortbildung_CME | Ausgabe 1/2021

Kohlenhydratreduktion

Paradigmenwechsel in den Empfehlungen zur Ernährung bei Typ-2-Diabetes

Zeitschrift:: Info Diabetologie > Ausgabe 1/2021

Autoren:: Dr. med. Katharina Lechner, Director of Research and Innovation PhD Amy L. McKenzie, Prof. Dr. oec. troph. Nicolai Worm

Typ-2-Diabetes (T2D) galt lange Zeit als chronisch progrediente Erkrankung. Dieses Verständnis änderte sich mit der Beobachtung von infolge von bariatrischer Therapie erzielten Diabetesremissionen. Inzwischen konnte gezeigt werden, dass auch Ernährungsinterventionen allein zu einer Verbesserung kardiometabolischer Risikoparameter, Einsparung von Medikamenten und Diabetesremission führen können. Dies sollte Anlass zu grundlegendem Umdenken in der Beratung von Patienten mit Diabetes mellitus Typ 2 geben. ...

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Jetzt einloggen Kostenlos registrieren

Anon. Diabetes mellitus Typ 2 - Strukturiertes Behandlungsprogramm. Hamburg: DAK-Gesundheit; 2020

[Anonym]. Nationale VersorgungsLeitlinie AWMF: Therapie des Typ-2-Diabetes, Kurzfassung 1. Auflage November 2014, AWMF-Register: Nr. nvl-001g In

Landgraf R, Aberle J, Birkenfeld AL et al. Therapie des Typ-2-Diabetes. Diabetologie 2019; 14: S167-S187

Taylor R. Pathogenesis of type 2 diabetes: tracing the reverse route from cure to cause. Diabetologia 2008; 51: 1781-1789. doi:10.1007/s00125-008-1116-7

Taylor R, Al-Mrabeh A, Sattar N. Understanding the mechanisms of reversal of type 2 diabetes. Lancet Diabetes Endocrinol 2019;7(9):726-736. doi: 10.1016/S2213-8587(19)30076-2

Gerst F, Wagner R, Kaiser G et al. Metabolic crosstalk between fatty pancreas and fatty liver: effects on local inflammation and insulin secretion. Diabetologia 2017; 60: 2240-2251. doi:10.1007/s00125-017-4385-1

Taylor R, Barnes AC. Can type 2 diabetes be reversed and how can this best be achieved? James Lind Alliance research priority number one. Diabet Med 2019; 36: 308-315. doi:10.1111/dme.13851

Al-Mrabeh A, Hollingsworth KG, Shaw JAM et al. 2-year remission of type 2 diabetes and pancreas morphology: a post-hoc analysis of the DiRECT open-label, cluster-randomised trial. Lancet Diabetes Endocrinol 2020. doi:10.1016/s2213-8587(20)30303-x

Al-Mrabeh A, Zhyzhneuskaya SV, Peters C et al. Hepatic Lipoprotein Export and Remission of Human Type 2 Diabetes after Weight Loss. Cell Metab 2020; 31: 233-249.e234. doi:10.1016/j.cmet.2019.11.018

10.

Zhyzhneuskaya SV, Al-Mrabeh A, Peters C et al. Time Course of Normalization of Functional β-Cell Capacity in the Diabetes Remission Clinical Trial After Weight Loss in Type 2 Diabetes. Diabetes Care 2020; 43: 813-820. doi:10.2337/dc19-0371

11.

Taylor R, Holman RR. Normal weight individuals who develop type 2 diabetes: the personal fat threshold. Clin Sci (Lond) 2015; 128: 405-410. doi:10.1042/cs20140553

12.

Lean MEJ, Leslie WS, Barnes AC et al. Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial. Lancet Diabetes Endocrinol 2019; 7: 344-355

13.

Lean ME, Leslie WS, Barnes AC et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. Lancet 2018; 391: 541-551. doi:10.1016/s0140-6736(17)33102-1

14.

Thom G, Messow CM, Leslie WS et al. Predictors of type 2 diabetes remission in the Diabetes Remission Clinical Trial (DiRECT). Diabet Med 2020;e14395. doi: 10.1111/dme.14395

15.

Taheri S, Zaghloul H, Chagoury O et al. Effect of intensive lifestyle intervention on bodyweight and glycaemia in early type 2 diabetes (DIADEM-I): an open-label, parallel-group, randomised controlled trial. Lancet Diabetes Endocrinol 2020; 8: 477-489. doi:10.1016/s2213-8587(20)30117-0

16.

McKenzie AL, Hallberg SJ, Creighton BC et al. A Novel Intervention Including Individualized Nutritional Recommendations Reduces Hemoglobin A1c Level, Medication Use, and Weight in Type 2 Diabetes. JMIR Diabetes 2017; 2: e5

17.

Athinarayanan SJ, Hallberg SJ, McKenzie AL et al. Impact of A Two-Year Trial of Nutritional Ketosis on Indices of Cardiovascular Disease Risk in Patients With Type 2 Diabetes. 2020;19(1):208. doi: 10.1186/s12933-020-01178-2

18.

Stock J. Triglycerides and cardiovascular risk: Apolipoprotein B holds the key. Atherosclerosis 2019; 284: 221-222

19.

Vilar-Gomez E, Athinarayanan SJ, Adams RN et al. Post hoc analyses of surrogate markers of non-alcoholic fatty liver disease (NAFLD) and liver fibrosis in patients with type 2 diabetes in a digitally supported continuous care intervention: an open-label, non-randomised controlled study. BMJ Open 2019; 9: e023597

20.

Hallberg SJ, McKenzie AL, Williams PT et al. Effectiveness and Safety of a Novel Care Model for the Management of Type 2 Diabetes at 1 Year: An Open-Label, Non-Randomized, Controlled Study. Diabetes Ther 2018; 9: 583-612

21.

Westman EC, Yancy WS, Jr., Humphreys M. Dietary treatment of diabetes mellitus in the pre-insulin era (1914-1922). Perspect Biol Med 2006; 49: 77-83

22.

Mann JI, De Leeuw I, Hermansen K et al. Evidence-based nutritional approaches to the treatment and prevention of diabetes mellitus. Nutr Metab Cardiovasc Dis 2004; 14: 373-94

23.

Toeller M. Was Ihr Diabetiker essen darf. MMW Fortschr Med 2006; 148: 41-43, 45-46

24.

Toeller M. Ernährungsempfehlungen bei Diabetes und deren Implementierung - Update anhand ausgewählter aktueller Publikationen. Diabetologe 2009; 5: 442-445

25.

Garg A. High-monounsaturated-fat diets for patients with diabetes mellitus. Am J Clin Nutr 1998; 67: 577S-82S

26.

Kodama S, Saito K, Tanaka S et al. Influence of fat and carbohydrate proportions on the metabolic profile in patients with type 2 diabetes: a meta-analysis. Diabetes Care 2009; 32: 959-965. doi: 10.2337/dc08-1716

27.

Cao Y, Mauger DT, Pelkman CL et al. Effects of moderate (MF) versus lower fat (LF) diets on lipids and lipoproteins: a meta-analysis of clinical trials in subjects with and without diabetes. Journal of Clinical Lipidology 2009; 3: 19-32

28.

Gannon MC, Nuttall FQ, Westphal SA et al. Acute metabolic response to high-carbohydrate, high-starch meals compared with moderate-carbohydrate, low-starch meals in subjects with type 2 diabetes. Diabetes Care 1998; 21: 1619-1626. doi:10.2337/diacare.21.10.1619

29.

Gannon MC, Nuttall FQ, Saeed A et al. An increase in dietary protein improves the blood glucose response in persons with type 2 diabetes. Am J Clin Nutr 2003; 78: 734-741. doi:10.1093/ajcn/78.4.734

30.

Nuttall FQ, Gannon MC, Saeed A et al. The metabolic response of subjects with type 2 diabetes to a high-protein, weight-maintenance diet. J Clin Endocrinol Metab 2003; 88: 3577-3583. doi:10.1210/jc.2003-030419

31.

Gannon MC, Nuttall FQ. Effect of a high-protein, low-carbohydrate diet on blood glucose control in people with type 2 diabetes. Diabetes 2004; 53: 2375-2382. doi:10.2337/diabetes.53.9.2375

32.

Nuttall FQ, Gannon MC. Metabolic response of people with type 2 diabetes to a high protein diet. Nutr Metab (Lond) 2004; 1: 6. doi:10.1186/1743-7075-1-6

33.

Gannon MC, Nuttall FQ. Control of blood glucose in type 2 diabetes without weight loss by modification of diet composition. Nutr Metab (Lond) 2006; 3: 16. doi:10.1186/1743-7075-3-16

34.

Nuttall FQ, Schweim K, Hoover H et al. Metabolic effect of a LoBAG30 diet in men with type 2 diabetes. Am J Physiol Endocrinol Metab 2006; 291: E786-791. doi:10.1152/ajpendo.00011.2006

35.

Nuttall FQ, Gannon MC. The metabolic response to a high-protein, low-carbohydrate diet in men with type 2 diabetes mellitus. Metabolism 2006; 55: 243-251. doi:10.1016/j.metabol.2005.08.027

36.

Nuttall FQ, Schweim K, Hoover H et al. Effect of the LoBAG30 diet on blood glucose control in people with type 2 diabetes. Br J Nutr 2008; 99: 511-519. doi:10.1017/s0007114507819155

37.

Gannon MC, Hoover H, Nuttall FQ. Further decrease in glycated hemoglobin following ingestion of a LoBAG30 diet for 10 weeks compared to 5 weeks in people with untreated type 2 diabetes. Nutr Metab (Lond) 2010; 7: 64. doi:10.1186/1743-7075-7-64

38.

Nuttall FQ, Gannon MC. Effect of a LoBAG30 diet on protein metabolism in men with type 2 diabetes. A Randomized Controlled Trial. Nutr Metab (Lond) 2012; 9: 43. doi:10.1186/1743-7075-9-43

39.

Snorgaard O, Poulsen GM, Andersen HK et al. Systematic review and meta-analysis of dietary carbohydrate restriction in patients with type 2 diabetes. BMJ Open Diabetes Res Care 2017; 5: e000354. doi:10.1136/bmjdrc-2016-000354

40.

Huntriss R, Campbell M, Bedwell C. The interpretation and effect of a low-carbohydrate diet in the management of type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials. Eur J Clin Nutr 2018; 72: 311-325. doi:10.1038/s41430-017-0019-4

41.

Sainsbury E, Kizirian NV, Partridge SR et al. Effect of dietary carbohydrate restriction on glycemic control in adults with diabetes: A systematic review and meta-analysis. Diabetes Res Clin Pract 2018; 139: 239-252

42.

Schwingshackl L, Chaimani A, Hoffmann G et al. A network meta-analysis on the comparative efficacy of different dietary approaches on glycaemic control in patients with type 2 diabetes mellitus. Eur J Epidemiol 2018; 33: 157-170. doi:10.1007/s10654-017-0352-x

43.

Tsaban G, Wolak A, Avni-Hassid H et al. Dynamics of intrapericardial and extrapericardial fat tissues during long-term, dietary-induced, moderate weight loss. Am J Clin Nutr 2017; 106: 984-995. doi:10.3945/ajcn.117.157115

44.

Gepner Y, Shelef I, Schwarzfuchs D et al. Effect of Distinct Lifestyle Interventions on Mobilization of Fat Storage Pools: CENTRAL Magnetic Resonance Imaging Randomized Controlled Trial. Circulation 2018; 137: 1143-1157. doi:10.1161/circulationaha.117.030501

45.

Gepner Y, Shelef I, Komy O et al. The Beneficial effects of Mediterranean diet over low-fat diet may be mediated by decreasing hepatic fat content. J Hepatol 2019;71(2):379-388. doi: 10.1016/j.jhep.2019.04.013. doi:WOOD10.1016/j.jhep.2019.04.013

46.

Worm N. Beyond Body Weight-Loss: Dietary Strategies Targeting Intrahepatic Fat in NAFLD. Nutrients 2020; 12. doi:10.3390/nu12051316

47.

Hu T, Bazzano LA. The low-carbohydrate diet and cardiovascular risk factors: evidence from epidemiologic studies. Nutr Metab Cardiovasc Dis 2014; 24: 337-343. doi:10.1016/j.numecd.2013.12.008

48.

Hu T, Yao L, Reynolds K et al. The Effects of a Low-Carbohydrate Diet vs. a Low-Fat Diet on Novel Cardiovascular Risk Factors: A Randomized Controlled Trial. Nutrients 2015; 7: 7978-7994. doi:10.3390/nu7095377

49.

Sackner-Bernstein J, Kanter D, Kaul S. Dietary Intervention for Overweight and Obese Adults: Comparison of Low-Carbohydrate and Low-Fat Diets. A Meta-Analysis. PLoS One 2015; 10: e0139817. doi:10.1371/journal.pone.0139817

50.

Mansoor N, Vinknes KJ, Veierod MB et al. Effects of low-carbohydrate diets v. low-fat diets on body weight and cardiovascular risk factors: a meta-analysis of randomised controlled trials. Br J Nutr 2016; 115: 466-479. doi:10.1017/s0007114515004699

51.

Skytte MJ, Samkani A, Petersen AD et al. A carbohydrate-reduced high-protein diet improves HbA(1c) and liver fat content in weight stable participants with type 2 diabetes: a randomised controlled trial. Diabetologia 2019; 62: 2066-2078. doi:10.1007/s00125-019-4956-4

52.

Skytte MJ, Samkani A, Astrup A et al. Effects of carbohydrate restriction on postprandial glucose metabolism, beta-cell function, gut hormone secretion, and satiety in patients with type 2 diabetes. Am J Physiol Endocrinol Metab 2021;320(1):E7-E18. doi: 10.1152/ajpendo.00165.2020

53.

Thomsen MN, Skytte MJ, Astrup A et al. The clinical effects of a carbohydrate-reduced high-protein diet on glycaemic variability in metformin-treated patients with type 2 diabetes mellitus: A randomised controlled study. Clin Nutr ESPEN 2020; 39: 46-52. doi:10.1016/j.clnesp.2020.07.002

54.

Unwin D, Khalid AA, Unwin J et al. Insights from a general practice service evaluation supporting a lower carbohydrate diet in patients with type 2 diabetes mellitus and prediabetes: a secondary analysis of routine clinic data including HbA1c, weight and prescribing over 6 years. BMJ Nutrition, Prevention & Health 2020; doi:10.1136/bmjnph-2020-000072

55.

Tay J, Thompson CH, Luscombe-Marsh ND et al. Nutritional adequacy of very low- and high-carbohydrate, low saturated fat diets in adults with type 2 diabetes: A secondary analysis of a 2-year randomised controlled trial. Diabetes Res Clin Pract 2020; 170: 108501. doi:10.1016/j.diabres.2020.108501

56.

Feinman RD, Pogozelski WK, Astrup A et al. Dietary carbohydrate restriction as the first approach in diabetes management: Critical review and evidence base. Nutrition 2015; 31: 1-13. doi:10.1016/j.nut.2014.06.011

57.

Hyde PN, Sapper TN, Crabtree CD et al. Dietary carbohydrate restriction improves metabolic syndrome independent of weight loss. JCI Insight 2019; 4 (12):e128308. doi: 10.1172/jci.insight.128308

58.

Gibson AA, Sainsbury A. Strategies to Improve Adherence to Dietary Weight Loss Interventions in Research and Real-World Settings. Behav Sci (Basel) 2017;7(3):44. doi:10.3390/bs7030044

59.

Davies MJ, D'Alessio DA, Fradkin J et al. Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2018; 41: 2669-2701. doi:10.2337/dci18-0033

60.

[Anonym]. 5. Lifestyle Management: Standards of Medical Care in Diabetes-2019. Diabetes Care 2019; 42: S46-S60

61.

Evert AB, Dennison M, Gardner CD et al. Nutrition Therapy for Adults With Diabetes or Prediabetes: A Consensus Report. Diabetes Care 2019; 42: 731-754

62.

Evert AB, Boucher JL, Cypress M et al. Nutrition therapy recommendations for the management of adults with diabetes. Diabetes Care 2014; 37 Suppl 1: S120-143

63.

Worm N, Lechner K. Sind Low-Carb-Diäten lebensgefährlich? Aktuel Ernährungsmed 2019; 44: 185-187

Titel: Kohlenhydratreduktion
Paradigmenwechsel in den Empfehlungen zur Ernährung bei Typ-2-Diabetes
Autoren:: Dr. med. Katharina Lechner
Director of Research and Innovation PhD Amy L. McKenzie
Prof. Dr. oec. troph. Nicolai Worm
Publikationsdatum: 26.02.2021
Schlagwörter: Typ-2-Diabetes
Stoffwechselkrankheiten und Ernährung
Ernährung
Fettleber
Diabetesschulung
Diabetestherapie
Prävention in der Diabetologie
Diabetes in der Hausarztpraxis
DOI: https://doi.org/10.1007/s15034-020-3646-0
Verlag: Springer Medizin
Zeitschrift: Info Diabetologie
Ausgabe 1/2021
Print ISSN: 1865-5459
Elektronische ISSN: 2196-6362

Praxisempfehlungen der Deutschen Diabetes Gesellschaft

Kurz, prägnant und aktuell: Die Praxisempfehlungen der Deutschen Diabetes Gesellschaft basieren überwiegend auf den evidenzbasierten Leitlinien und den evidenzbasierten nationalen Versorgungsleitlinien der DDG und werden jährlich dem Stand der Wissenschaft angepasst.

Zu den Praxisempfehlungen

Bildnachweise

Springer Medizin

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2021

Schutzmechanismus vor Insulinresistenz im Gehirn entdeckt

Erhöhte Hypo-Gefahr bei entzündlicher Darmerkrankung

Cave Schnittstellenproblem in "Coronazeiten" bei diabetischem Notfall

Kinder von Frauen mit Typ-1-Diabetes erkranken häufiger an Multipler Sklerose

So hat Corona der Diabetesversorgung genutzt und geschadet

Keine Angst vor Nahrungsfett!

Praxisempfehlungen der Deutschen Diabetes Gesellschaft